Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2004-10-18
2010-06-22
Nickol, Gary B (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
C424S185100, C424S192100, C424S198100, C514S002600, C530S324000
Reexamination Certificate
active
07740833
ABSTRACT:
Variants of homodimer-forming chemokines, such as human CCL2, having a single amino acid substitution in the dimerization interface that alters the pattern of hydrogen bonds and acting as an obligate monomer, can antagonize natural chemokines and have anti-inflammatory activity in vivo. These variants can be used as active ingredient in pharmaceutical compositions for the treatment of inflammatory, autoimmune, or infectious diseases.
REFERENCES:
patent: 5705360 (1998-01-01), Rollins et al.
patent: 5739103 (1998-04-01), Rollins et al.
patent: 5993814 (1999-11-01), Williams et al.
patent: 6100387 (2000-08-01), Herrmann et al.
patent: 6617135 (2003-09-01), Gillies et al.
patent: WO 03/083059 (2003-10-01), None
patent: WO 03/084993 (2003-10-01), None
patent: WO 2007/113285 (2007-10-01), None
Serbina et al. Annu. Rev Immunol. 2008. 26:421-52.
Dawson et al. 2003. Expert Opin Ther. Targets 7:35-48.
Loetscher et al. J Leukocyte Biology 69:881-884.
Bowie et al, 1990, Science 247:1306-1310.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds, Birkhauser, Boston, pp. 433-506.
Wells, 1990, Biochemistry 29:8509-8517.
Wang et al. 2001. J. Biol Chem. 276:49213-49220.
Hemmerich, S. et al. “Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2”Biochemistry, Oct. 5, 1999, pp. 13013-13025, vol. 38, No. 40.
Kim, K-S. et al. “Structural characterization of a monomeric chemokine: Monocyte chemoattractant protein-3”FEBS Letters, 1996, pp. 277-282, vol. 395, Nos. 2-3.
Paavola, C.D. et al. “Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B”Journal of Biological Chemistry, Dec. 11, 1998, pp. 33157-33165, vol. 273, No. 50.
Proudfoot, A.E.I, et al. “Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines”PNAS, Feb. 18, 2003, pp. 1885-1890, vol. 100, No. 4.
Jarnagin, K. et al. “Identification of surface residues of the monocyte chemotactic protein 1 that affect signalng through the receptor CCR2”Biochemistry, 1999, pp. 16167-16177, vol. 38, No. 49.
Lau, E.K. et al. “Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1”Journal of Biological Chemistry, May 21, 2004, pp. 22294-22305, vol. 279, No. 21.
Brini, E. et al. “Clinical, neuropathological and immunological effects of the administration of a MCP-1 variant on Relapsing-Remitting experimental autoimmune encephalomyelitis mouse model”, abstract and poster to be presented at the 23rdCongress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) conference, Prague, Czech Republic, Oct. 11-14, 2007.
Johnson, Z. “The Role of Glycosaminoglycan Binding and Oligomerisation in Chemokine Function in Vivo”, thesis catalogued on Jul. 13, 2004 in the Senate House Library, University of London, pp. 1-273.
Johnson Zoe
Proudfoot Amanda
Shaw Jeffrey
Merck Serono SA
Nickol Gary B
Saliwanchik Lloyd & Saliwanchik
Shafer Shulamith H
LandOfFree
Therapeutic uses of chemokine variants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic uses of chemokine variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic uses of chemokine variants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4208286